<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241043</url>
  </required_header>
  <id_info>
    <org_study_id>PAKT CTC 151043</org_study_id>
    <nct_id>NCT03241043</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients</brief_title>
  <official_title>Single Center, Open-label, Randomized, Controlled, Cross Over Study to Evaluate the Pharmacokinetic and Bioavailability of Envarsus® in Comparison to Advagraf® in de Novo Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, open-label, randomized, controlled, cross over study to evaluate the
      pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver
      transplant recipients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using an open-label, randomized, controlled, 2-period cross-over design, two treatments
      (Envarsus® and Advagraf®) will be compared (with regard to PK profile and bioavailability)
      after administration of IMP to 20 de novo transplanted recipients. The patients will be
      randomly assigned to one of the two treatments as treatment period 1 and afterwards switched
      to treatment period 2 (Group 1: Envarsus® - Advagraf®; Group 2: Advagraf® - Envarsus®).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAV (average cumulative dose) = cumulative dose per study period/ period days</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C0/doses (trough level at steady state / daily dose at steady state)</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24/doses</measure>
    <time_frame>20 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Envarsus - Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advagraf - Envarsus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 2 weeks Envarsus followed by 2 weeks Advagraf</intervention_name>
    <arm_group_label>Envarsus - Advagraf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 2 weeks Advagraf followed by 2 weeks Envarsus</intervention_name>
    <arm_group_label>Advagraf - Envarsus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand the patient information and to personally sign and date the
             informed consent to participate in the clinical trial, before completing any clinical
             trial related procedures.

          2. Male or female recipients ≥ 18 years of a liver graft from a deceased or living donor

          3. The patient must receive a twice daily Tacrolimus based immunosuppression treatment.

          4. Females of child-bearing potential who agree to comply with any applicable
             contraceptive requirements of the protocol or females who are permanently sterilized
             (at least 6 weeks post sterilization).

          5. Non-pregnant, non-lactating female.

          6. Recipients of a first or re-liver transplant in the last 30 days

          7. The patient is co-operative and available for the entire clinical trial.

        Exclusion Criteria:

          1. Patients with a known hypersensitivity to any of the drugs used in the study.

          2. Patients who are not able to take oral medication at the time point of randomization.

          3. Recipients of combined organ transplants.

          4. Patients who are recipients of AB0 incompatible transplant grafts.

          5. Currently participation in a clinical trial and any IMP intake within the last four
             weeks.

          6. Patients who use drugs known to strongly interact with the cytochrome P-450 3A4
             pathway and therefore influence the tacrolimus blood level are not allowed during
             Envarsus®/Advagraf® treatment period.

          7. Patient with renal impairment with need of dialysis treatment at the time point of
             randomization.

          8. Patient with a quick value &lt; 30 %

          9. Patient with a thrombocytopenia &lt;20 Mrd./L

         10. Patients with a leukopenia &lt; 1.0 Mrd. / L

         11. Patients with inability of oral food intake.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uta Herden, PD Dr.</last_name>
    <email>u.herden@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjoern Nashan, PD Dr.</last_name>
    <email>nashan@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Herden, PD Dr.</last_name>
      <email>u.herden@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <keyword>Comparing Envarsus versus Advagraf</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

